Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAPEZE: Docetaxel combinations in bone metastatic prostate cancer
NCT00554918Phase 2Completed
- Sponsor
- University Hospitals Birmingham
- Start
- Feb 2005
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zoledronic acid and strontium-89 in prostate cancer (PCa) (4 arms), sponsored by University Hospitals Birmingham. Primary endpoints: Toxicity and tolerability of docetaxel with zoledronic acid, Toxicity and tolerability of docetaxel with strontium chloride Sr 89 and 1 more. Started Feb 2005; status: completed.
02
Drugs
zoledronic acidstrontium-89
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00554918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00554918.